Natera, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Natera reported Q2 2026 revenues of $752.8M vs. $546.6M in Q2 2025 (37.7% growth). Test volumes grew 22.4% to 1.04M, with clinical MRD oncology tests surging 57.2% to 297K. Gross margin improved to 64.5% from 63.4% YoY. Company raised full-year 2026 revenue guidance to $2.85B–$2.91B (from $2.74B–$2.82B), a $100M midpoint increase. Net loss narrowed to $67M (–$0.47/share) vs. $101M (–$0.74/share) YoY. Cash position: $1.09B; debt $80.3M on UBS line.
Why this rating
Strong revenue growth (38% YoY) and margin expansion; guidance raise signals execution. But $752.8M Q2 revenue is ~3.5% of $21.8B market cap annualized. Still unprofitable; modest relative magnitude.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.